Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06894875

Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance

Examining the Safety and Tolerability of Lentil Protein Hydrolysate in Healthy Males and Females Whilst Exploring the Effects of a Dose Range on Blood Pressure Control and Vascular Function and Exercise Performance

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
48 (estimated)
Sponsor
Nuritas Ltd · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance

Detailed description

The aim of this trial is to evaluate the safety and tolerability of a lentil protein hydrolysate (LPH) in healthy participants while exploring effects on blood pressure control, vascular function and exercise performance. The study will be conducted in men and women over 4 weeks. Specifically, the study has three key objectives: 1. To determine the safety and tolerability of 500 - 2000mg of a novel plant-based supplement LPH) in healthy volunteers as assessed via AE reporting, changes in clinic blood pressure and supplementation induced orthostatic hypotension during a sit-to-stand challenge. 2. To explore the effects of 4-weeks of lentil protein hydrolysate supplementation on markers of vascular age and endothelial function, fatigue, quality of life, and grip strength. 3. To explore the effects of 4-weeks of LPH supplementation on markers of exercise performance, including cardiorespiratory fitness (VO2max) and substrate utilisation during sub-maximal, steady-state exercise. This trial incorporates a wearable device to measure physical activity, cardiac health, sleep metrics and heart rate variability.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTLentil protein hydrolysatePlant protein hydrolysate
DIETARY_SUPPLEMENTPlacebo MCC micro-crystalline cellulosePlacebo MCC micro-crystalline cellulose

Timeline

Start date
2025-06-24
Primary completion
2025-12-24
Completion
2026-03-30
First posted
2025-03-25
Last updated
2025-12-16

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT06894875. Inclusion in this directory is not an endorsement.